CDIP1 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA520697-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA520697 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
CDIP1
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CDIP1
Gene Alias
2700048O17Rik; 5730403B10Rik; AU018521; AW742692; C16orf5; CDIP; CDIP1; cell death inducing protein; cell death inducing Trp53 target 1; cell death involved p53-target; cell death-inducing p53 target 1; cell death-inducing p53-target protein 1; Cell death-inducing protein; I1; Lipopolysaccharide-induced tumor necrosis factor-alpha-like protein; LITAFL; LITAF-like protein; Transmembrane protein I1
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
29965, 66626
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
Q9DB75, Q9H305
Gene Symbols
CDIP1
Immunogen
A 19 amino acid peptide near the center of human CDIP.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is human brain tissue lysate
- PA5-20697 can be used with blocking peptide PEP-0812
- The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers
- CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses
- Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway
- CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy
- Multiple isoforms of CDIP are known to exist.